SVA Share Price

Open 0.25 Change Price %
High 0.25 1 Day -0.02 -7.69
Low 0.24 1 Week -0.01 -4.00
Close 0.24 1 Month -0.01 -4.00
Volume 64000 1 Year 0.01 4.35
52 Week High 0.40
52 Week Low 0.21
SVA Important Levels
Resistance 2 0.25
Resistance 1 0.25
Pivot 0.24
Support 1 0.23
Support 2 0.23
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
MCG 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
BVQ 0.02 100.00%
ZMD 0.02 100.00%
DDX 0.50 100.00%
PTR 0.02 100.00%
PTR 0.02 100.00%
PTR 0.02 100.00%
SVT 0.04 100.00%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
IXI 0.02 -50.00%
KLM 0.01 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

Sernova Corp (CVE: SVA)

SVA Technical Analysis 5
As on 22nd Feb 2017 SVA Share Price closed @ 0.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.28 & Strong Sell for SHORT-TERM with Stoploss of 0.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
SVA Target for February
1st Target up-side 0.3
2nd Target up-side 0.33
3rd Target up-side 0.36
1st Target down-side 0.22
2nd Target down-side 0.19
3rd Target down-side 0.16
SVA Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.sernova.com
SVA Address
SVA
700 Collip Circle
Suite 114
London, ON N6G 4X8
Canada
Phone: 519-858-5184
Fax: 519-858-5099
Interactive Technical Analysis Chart Sernova Corp ( SVA CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sernova Corp
SVA Business Profile
Sernova Corp., a clinical-stage health sciences company, focuses on the development and commercialization of medical technologies. The company’s proprietary platform technologies include Cell Pouch System, a scalable device providing a natural organ-like environment for therapeutic cells, such as insulin producing islets for diabetics; and Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. It also intends to commercialize the products for parkinson’s, spinal cord injury, and haemophilia diseases. The company is headquartered in London, Canada.